EDAP TMS SA

EDAP TMS S.A. is a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices. The company's legal name is EDAP TMS S.A., and its commercial name is Focal One®. Founded in 1979 as a société anonyme under French law for a duration of 60 years, EDAP TMS S.A. is headquartered in Vaulx-en-Velin, France. The company operates in the United States, Europe, Asia, and the rest of the world, and is listed on The Nasdaq Global Market under the symbol "EDAP." Its technologies are primarily used in urology, with a current focus on the treatment of prostate cancer. EDAP TMS S.A. is conducting clinical development activities for potential expanded indications in urology and women's health. The company has realigned its business to focus exclusively on applications leveraging its proprietary High Intensity Focused Ultrasound ("HIFU") technology, commercially driven by its flagship product, Focal One® Robotic HIFU. Focal One obtained a CE Marking for the treatment of prostate cancer on June 18, 2013, allowing its commercialization in the European Union and other territories requiring CE Marking. On June 7, 2018, the company received U.S.